Introduction
Lung cancer is the leading cause of cancer death for both men and women. In 2013, an estimated 228,190 new cases of lung cancer were diagnosed and 159,480 deaths occurred. 1 Non-small-cell lung cancers (NSCLCs) are staged from I to IV. Stage III locally advanced NSCLC is composed of a heterogeneous group of patients due to differences in the size and location of the primary tumor and nodal disease. Stage IIIA NSCLC accounts for approximately one-quarter prove survival over CRT alone in stage IIIA NSCLC. 5 However, in a post hoc, exploratory, subset analysis, the investigators reported a significant improvement in overall survival (OS) for patients undergoing CRT followed by lobectomy vs CRT alone. Patients who underwent a pneumonectomy, however, did not fare better than patients who underwent CRT alone. In the group treated with surgery, there were 16 deaths, 14 of whom had a pneumonectomy. The higher upfront mortality seen in pneumonectomy patients may have at least partially contributed to the lack of survival benefit over CRT alone.
Thus, the role of surgery in patients with stage IIIA (N2) disease remains to be defined. Preliminary evidence suggests that select patients whose tumors are amenable to lobectomy may derive survival benefit from the incorporation of surgery in their multimodality approach compared to patients treated with CRT alone. We report the outcomes of stage IIIA patients treated at a tertiary referral cancer center by a multidisciplinary team of surgical, medical, and radiation oncologists.
Materials and Methods
Patients with stage IIIA NSCLC treated between January 2000 and December 2008 at Fox Chase Cancer Center were identified from the tumor registry. Approval was obtained from the Center's institutional review board (#09-814) for retrieval of patient records for review and analysis. Patients were included in the analysis if they had clinically or pathologically proven stage IIIA disease (either T3N1 or T1-3N2, identical to those enrolled in the INT 0139 trial) and were treated with concurrent CRT with or without surgery. Patients with stage IIIB disease or malignant pleural effusion and those undergoing single-modality treatment were excluded.
Recorded patient information included age at diagnosis, sex, Eastern Cooperative Oncology Group performance status (ECOG PS) at diagnosis, T and N stage, histology, smoking status, date of diagnosis, type of surgery, chemotherapy, radiation therapy, timing of CRT, sites, date of relapse/progression, and date of death or date last seen alive.
Definitions
Smoking status was classified as current smoker (actively smoking at the time of diagnosis or quit within 1 year of diagnosis), never smoker (< 100 cigarettes smoked in a lifetime), and former smoker (quit smoking > 1 year prior to diagnosis). Histology was reported according to the World Health Organization classification of lung tumors. 8 ECOG PS was obtained from the initial history and physical examination. Surgery was classified as lobectomy, pneumonectomy, or other (eg, wedge resection). Only patients undergoing pneumonectomy and lobectomy were included in the analysis of patients who proceeded to resection. Clinical stage and TNM stage were defined according to the 6th edition of the AJCC guidelines, 9 which was operative at the time these patients were seen.
Statistical Analysis
The goal of our study was to determine if OS was superior in patients undergoing anatomic resection as part of a trimodality approach compared with patients undergoing bimodal CRT alone. Specifically, we sought to discern the clinical benefit of incorporating surgery in the treatment schema of patients treated in a specialized multidisciplinary setting. We used a rigorous propensity score adjustment method to offset the selection bias that inevitably occurs while deciding whether surgery should or should not be incorporated in a patient's treatment plan. The patients were divided into 3 groups by the nature of their treatment: CRT alone, CRT followed by pneumonectomy, and CRT followed by lobectomy. To adjust for baseline demographics and tumor-related differences and selection bias among the 3 treatment groups, we used propensity score-based weighting. 10 Similar propensity score-based weighting has been used in a variety of settings to investigate treatment effects using observational data. 11, 12 After the propensity score-based weighting was applied, all groups were balanced for age, sex, ECOG PS, T stage, N stage, smoking status, and histology. Since there were 3 groups of interest, we used multinomial logistic regression to estimate the generalized propensity scores, as described previously. 13 The adequacy of the propensity score model was verified by examining adjusted differences in potential confounder variables among the three treatment groups. The lack of statistically significant differences in propensity score adjusted averages of the confounder variables among the three groups suggests that there could not be confounders after adjustment.
To examine adjusted survival differences among the three arms, we weighted Cox proportional hazards regressions in which the treatment arms were entered as covariates. The treatment effects of interest reflect the effect of treatment in the propensity score adjusted population. We used bootstrap standard errors for all hypotheses testing.
14 The bootstrap standard errors accounted for the fact that the weights were estimated rather than known. Hazard ratios (HRs) for each of the variables were calculated with 95% confidence intervals and P values. All P values were two-sided, and P values < .05 were considered significant. The analyses were conducted using STATA version 10 (Stata Corp, College Station, Texas). Weighted Kaplan-Meier estimators in STATA 10 were used to generate adjusted 1-, 2-, and 5-year survival curves.
Results

Patient Characteristics
A total of 249 patients with clinical stage IIIA (T3N1 and T1-3N2) NSCLC treated at the Fox Chase Cancer Center between January 2000 and December 2008 were included in this analysis. The median age was 65 years, and 43% were men. Most patients (96.5%) had N2 disease. Of the 249 patients, 103 underwent CRT alone, and 146 underwent surgery as part of trimodality therapy (pneumonectomy = 41 and lobectomy = 105). Information about radiation doses was available for 160 patients. Median dose of radiation was 50.4 Gy in the definitive CRT group (range, 30.6 to 70 Gy) and 50.4 Gy in the surgical group (range, 30 to 66 Gy). Patient demographics are shown in Table 1 . In the unadjusted data set, younger patients and patients with ECOG PS of 0 were more likely to undergo pneumonectomy (P = .042 and P = .023, respectively). Women were more likely to undergo lobectomy (61% vs 46%, P = .04). Patients with squamous cell histology were more likely to undergo pneumonectomy (46%). There were no differences in demographics and treatment selection based on smoking history and nodal status. A greater proportion of patients in the surgical group had T2 disease (P = .001) as opposed to T1 or T3 disease. After propensity score-based weighting, the groups were balanced for age, sex, ECOG PS, smoking history, histology, and T and N stages (Table  2 ; P > .3 for pair-wise comparisons).
Patterns of Recurrence and Perioperative Mortality
Detailed posttherapy follow-up information was available on 176 patients (71%). Seventy-three patients (29%) elected to pursue follow-up care elsewhere; thus, their follow-up information was unavailable. Local recurrence, as documented by radiography and pathology, was seen in 20 patients (19%) in the CRT group, in 20 patients (19%) in the lobectomy group and in 4 patients (10%) who underwent pneumonectomy. The rate of distant recurrence was 33% for CRT, 28% for lobectomy, and 39% for pneumonectomy (Table  3) . Of 146 patients who underwent surgery, 6 patients died within 30 days of their surgery, 3 in the lobectomy group and 3 in the pneumonectomy group.
Survival Analysis
The median OS for the entire cohort was 24 months (Fig 1) . Survival outcomes were superior in the surgical cohort compared with the nonsurgical cohort. The median OS was 30.9 months for patients who underwent surgery vs 20.2 months for the patients who did not (P = .005; log-rank; Fig 2) .
Pneumonectomy was not associated with a statistically significant survival benefit over CRT (median OS = 28 months vs 22 months, P = .534 after propensity score adjustment, hazard ratio [HR] = 0.80; Fig 3) . Lobectomy yielded superior OS compared with CRT (median OS = 39 months vs 22 months, P = .038, HR = 0.62). Lobectomy patients had higher 1-, 2-, and 5-year OS rates (88%, 63%, and 40%, respectively) compared with CRT patients (75%, 45%, and 29%, respectively; Fig 4) . The survival differences in the lobectomy vs CRT comparison were statistically significant at the 10% false discovery rate level.
Discussion
Management and treatment of stage IIIA NSCLC are among the more controversial areas in the field of thoracic oncology. To date, there are no standard approaches, especially for patients with stage III single-and multistation "nonbulky" nodal disease. Chemotherapy (neoadjuvant, combined with radiation or adjuvant), radiation therapy (combination or postoperative), and surgery (pneumonectomy Table 1 or lobectomy), either alone or in various combinations with chemotherapy and radiation, have been evaluated in numerous studies. [15] [16] [17] [18] [19] [20] [21] Two multicenter randomized trials were performed to examine the benefit of surgery in stage IIIA (N2) disease. The European Organisation for Research and Treatment of Cancer (EORTC) completed a large randomized phase III trial that compared surgery vs radiotherapy in patients with stage IIIA (N2) disease who responded to induction chemotherapy and who were initially considered unresectable. 7 The guidelines for initial unresectability were (1) any N2 involvement by a nonsquamous carcinoma, and (2) in case of squamous cell carcinoma, any N2 nodal involvement exceeding level 4R for a right-sided tumor and levels 5 and 6 for a left-sided tumor. N2 disease found only at thoracotomy after a negative staging mediastinoscopy was not necessarily considered unresectable. Of the 579 patients who received induction chemotherapy, 61% demonstrated a response (complete, partial, or minor). Of the 165 patients who underwent surgery, 40% received postoperative radiation for incomplete resection. Another 165 received sequential radiotherapy without surgery. There was no difference in median survival (17.5 months vs 16.4 months) or 5-year survival rate (14% vs 15.7%) between the nonsurgical and surgical arms, respectively, supporting the conclusion that some combination of chemotherapy and radiotherapy is the treatment of choice for unresectable patients with stage IIIA (N2) disease. The study design arguably favored the surgical arm because the nonsurgical arm received sequential rather than concurrent CRT, which had been shown to improve survival in patients with locally advanced, unresectable NSCLC. 7, 17, 19, 22 Despite this potential bias, surgery failed to yield an improvement in survival.
The INT 0139 trial randomized 429 patients with T1-3 and biopsy-proven N2 NSCLC and good ECOG PS to either induction CRT followed by surgery or consolidative radiotherapy. In contrast to the EORTC trial discussed above, patients had to be technically resectable at the time of randomization, and the vast majority of patients accrued in either arm had single-station nodal disease (76%). OS was similar between the groups (23.6 and 22.2 months). However, a post-hoc subset analysis suggested superior OS for trimodality patients undergoing lobectomy compared with patients matched by baseline demographics who underwent CRT alone; the median OS was 33.6 months for the lobectomy group compared with 21.7 months for the CRT group (P = .002). At 5 years, 21 of 90 patients (point estimate 36%) vs 10 of 90 (point estimate 18%), respectively, were alive. However, because 
Sex:
Male Because of rounding, percentages may not total 100. CRT = concurrent chemoradiation therapy, ECOG PS = Eastern Cooperative Oncology Group Performance Status, NOS = not otherwise specified, SD = standard deviation. this analysis was unplanned and retrospective, these findings can be considered only hypothesis-generating and inconclusive. 5 In our single-center experience treating patients with stage IIIA NSCLC, we found that younger patients (< 70 years of age), women, and those with an ECOG PS of ≤ 1 at presentation were more likely to undergo surgery. More patients with squamous cell tumors underwent pneumonectomy, most likely due to the central nature of these tumors. Nevertheless, when we balanced factors such as age, ECOG PS, histology, and T and N stages by the propensity score analysis, we were left with a homogenous population across three different treatment subgroups, and the survival benefit for lobectomy essentially persisted. OS was superior in the surgical group compared with the nonsurgical group. Similar to the INT 0139 experience, we also demonstrated an advantage for patients undergoing lobectomy rather than pneumonectomy as part of trimodality treatment. All surgical resections in this series were performed at a single tertiary referral center. Patients who underwent surgery were carefully selected and constituted a more favorable group (younger age, better ECOG PS) compared with patients who underwent CRT alone. In addition, those receiving CRT alone appear to have received suboptimal doses of radiation therapy (median 50.4 Gy), which may have compromised outcome in the nonsurgical group. We suspect that the majority of those who received less than 60 Gy did so because radiation therapy was typically halted while potential surgical candidates underwent additional preoperative testing. The majority of those individuals who, for one reason or another, failed to go on to surgery did not receive full-dose radiation therapy. To prevent this from occurring in the daily management of patients, we suggest that patients selected for a surgical approach after induction therapy should be resectable Months by lobectomy at the time of diagnosis. In other words, induction therapy should not be used with the intent of rendering an unresectable tumor resectable.
Conclusions
Our results corroborate the findings of the randomized INT 0139 study. The question of whether lobectomy after induction concurrent chemoradiation therapy (CRT) truly adds a survival benefit over definitive CRT alone remains unanswered. Therefore, we propose that a formal randomized trial comparing induction CRT followed by a lobectomy vs definitive CRT be performed in patients with stage IIIA disease whose tumors are potentially resectable by a lobectomy at the time of diagnosis. In the absence of a clear survival benefit for patients undergoing pneumonectomy after CRT, and with the high mortality rates outside of experienced centers, 23,24 pneumonectomy should not be considered part of clinical practice in the trimodality setting. Patients who would require pneumonectomy after induction therapy are likely best served by definitive CRT.
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